# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0209 |
| PP ID | PP-0209 |
| Title | Targeted Therapy in Gastric Cancer |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Decision Status | APPROVED / LOCKED |
| Gold Standard | FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1 |
| Governance Standard | CORE_WORKING_RULES v1.7 |
| Last Updated | 2026-08-09 |

---

# 1. QA Decision

## Final Decision

# PASS — GOLD — READY FOR INTEGRATION

The four-artifact package was produced after the PP-0209 Decision Batch was explicitly approved and locked.

No architecture blocker remains within the locked scope.

The package preserves the modality-level ownership of targeted therapy and does not convert the package into a drug-specific prescribing library.

# 2. Artifact Completeness QA

| Required Artifact | Present | Status |
|---|---|---|
| 01_CKO.md | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | PASS |
| 04_QA_REPORT.md | Yes | PASS |
| Single ZIP package | Yes | PASS |
| PP ID in filenames/package | Yes | PASS |
| Title in package filename | Yes | PASS |
| Boundary declared in final response | Required | PASS |

No required artifact is omitted.

# 3. Governance Compliance QA

## WR-009 — Gold Template & Source Reference Adherence

**Result: PASS**

The package follows the established Gold artifact architecture.

No artifact has been intentionally compressed into a summary.

## WR-010 / WR-010A — Immediate Gold Production

**Result: PASS**

Production was performed immediately after explicit approval and lock.

No additional format/depth confirmation was requested.

## WR-010B — Final Response

**Result: PASS**

Final delivery includes:

1. ZIP package;
2. artifact confirmation;
3. Boundary;
4. standardized QA final status.

## WR-010C — Boundary

**Result: PASS**

Boundary uses:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

## WR-010D — User-Controlled Continuation

**Result: PASS**

No subsequent PP was selected automatically.

# 4. Gold Depth QA

## Result: PASS

The package was produced at full Gold depth.

The artifacts retain:

- complete educational reasoning;
- scope analysis;
- evidence traceability;
- Knowledge Graph treatment;
- patient-facing explanations;
- evidence gaps;
- safety guardrails;
- adjacent-package routing;
- detailed QA.

No artifact was intentionally shortened to a minimal implementation.

The package therefore follows the project's absolute Gold-depth rule.

# 5. CKO QA

## Scope

**PASS**

The CKO answers one atomic question:

> What is targeted therapy for gastric cancer, how is it different from chemotherapy and immunotherapy, when can it be used, and why do biomarker results matter?

## Patient-centeredness

**PASS**

The CKO explains:

- what targeted therapy means;
- why biomarker testing matters;
- what a target means;
- what patients can expect conceptually;
- why response is not guaranteed;
- what questions to ask.

## Clinical governance

**PASS**

No individualized prescribing is included.

## Knowledge Graph

**PASS**

Upstream, current, downstream, parallel, and routing relationships are explicitly defined.

## Boundary

**PASS**

The CKO preserves ownership boundaries with biomarker-testing and therapy-specific packages.

# 6. Knowledge Passport QA

## Runtime Classification

**PASS**

PP-0209 is classified as:

- treatment modality;
- precision-oncology framework;
- patient-facing clinical education.

## Retrieval Intent

**PASS**

The passport contains explicit retrieval triggers and non-retrieval conditions.

## Routing

**PASS**

HER2, CLDN18.2, anti-angiogenic, biomarker-testing, and systemic-treatment questions are routed to the appropriate package.

## Safety

**PASS**

The passport contains guardrails against:

- automatic treatment selection;
- guaranteed-response claims;
- dose recommendations;
- unsupported sequencing.

# 7. Evidence Package QA

## Primary Source Hierarchy

**PASS**

NCCN v2.2026 is the primary disease-specific guideline source.

NCI PDQ, NCI patient-facing material, ACS, and ESMO-ASCO are used according to their appropriate roles.

## Evidence Matrix

**PASS**

Important claims are mapped to source families.

## Evidence Gaps

**PASS**

The package explicitly records:

- rare-target evidence limitations;
- evolving guidelines;
- tumor heterogeneity;
- assay limitations;
- response heterogeneity;
- resistance;
- real-world applicability.

## Trial Evidence

**PASS**

Representative trials are used to establish modality-level principles rather than duplicate downstream therapy packages.

# 8. Source-Grounded Clinical Content QA

## Result: PASS

Clinical claims are grounded in the supplied project sources.

The key disease-specific source confirms:

- HER2-directed first-line treatment;
- CLDN18.2-directed first-line treatment;
- subsequent ramucirumab-containing therapy;
- HER2-directed subsequent treatment;
- selected NTRK, BRAF V600E and RET pathways.

NCI and ACS independently support the patient-facing targeted-therapy concept and selected treatment examples.

No unsupported universal treatment rule has been added.

# 9. Targeted Therapy Definition QA

## Result: PASS

The package defines targeted therapy as a treatment modality based on a specific biological target.

It does not define targeted therapy as:

- mutation-only;
- side-effect-free;
- universally superior;
- guaranteed to work.

This is clinically safer and more faithful to the source architecture.

# 10. Biomarker Boundary QA

## Result: PASS

PP-0209 explains the **therapeutic relevance** of biomarker information.

It does not reproduce:

- detailed HER2 scoring;
- CLDN18.2 scoring;
- PD-L1 scoring;
- MSI/MMR assay methodology;
- NGS laboratory methodology;
- variant classification.

This preserves the boundary with PP-0191 and the individual biomarker-testing packages.

# 11. PP-0190 Boundary QA

## Result: PASS

PP-0190 owns the biomarker-directed treatment-selection bridge.

PP-0209 owns the broader treatment-modality explanation.

The package does not reproduce the complete clinical decision algorithm of PP-0190.

Routing remains:

**testing**

→ PP-0191

**biomarker-directed selection**

→ PP-0190

**targeted therapy modality**

→ PP-0209

**target-specific treatment**

→ downstream PPs.

# 12. PP-0208 Boundary QA

## Result: PASS

PP-0208 owns broad palliative systemic-treatment strategy and sequencing.

PP-0209 owns targeted therapy as a treatment modality.

PP-0209 does not reproduce:

- complete treatment-line algorithms;
- all systemic-treatment options;
- global palliative treatment selection.

This is a major overlap safeguard.

# 13. HER2 Boundary QA

## Result: PASS

PP-0209 contains:

- why HER2 is a targeted-treatment paradigm;
- high-level HER2-treatment relationship;
- representative trastuzumab/T-DXd examples.

PP-0209 does not contain:

- detailed HER2 testing;
- detailed trastuzumab management;
- detailed T-DXd management;
- therapy-specific cardiac monitoring;
- therapy-specific resistance management.

These are delegated to PP-0210 and relevant downstream packages.

# 14. CLDN18.2 Boundary QA

## Result: PASS

PP-0209 contains:

- CLDN18.2 as a target;
- biomarker-directed treatment concept;
- representative zolbetuximab evidence.

PP-0209 does not contain:

- detailed CLDN18.2 assay interpretation;
- detailed zolbetuximab administration;
- therapy-specific toxicity management;
- detailed CLDN18.2 treatment sequencing.

These belong to PP-0211 and downstream packages.

# 15. Anti-Angiogenic Boundary QA

## Result: PASS

Ramucirumab is used as a representative example of pathway/receptor-directed therapy.

PP-0209 does not become an anti-angiogenic therapy package.

Detailed ramucirumab treatment and anti-angiogenic management are delegated to PP-0212.

# 16. Rare Actionable Alterations QA

## Result: PASS

NTRK, BRAF V600E and RET are included as supporting examples.

They are not given disproportionate depth.

The package does not imply that:

- these alterations are common in gastric cancer;
- every patient should be tested in the same way;
- an alteration automatically determines treatment.

The evidence is explicitly labeled as selected/context-dependent.

# 17. Treatment-Line QA

## Result: PASS

The package explicitly distinguishes:

- first-line targeted-treatment examples;
- subsequent-line targeted-treatment examples;
- selected alteration-directed treatment.

This prevents the unsafe inference:

> “A targeted drug exists, therefore it should be used immediately.”

Prior therapy and clinical context are preserved.

# 18. Combination-Therapy QA

## Result: PASS

The package correctly explains that targeted therapy can be:

- combined with chemotherapy;
- included in selected broader combinations;
- used alone in selected molecularly defined settings.

It does not imply that any combination is universally appropriate.

# 19. Targeted Therapy vs Chemotherapy QA

## Result: PASS

The package makes the distinction at a conceptual level without using an absolute “specific versus nonspecific” oversimplification.

It correctly explains that targeted therapy may still have substantial toxicity.

# 20. Targeted Therapy vs Immunotherapy QA

## Result: PASS

The package distinguishes:

- molecular/biological targeting;
- immune-system targeting/modulation.

It also recognizes that the modalities may be combined.

No modality is presented as universally superior.

# 21. Biomarker-Positive Does Not Equal Response QA

## Result: PASS

The package explicitly states that a positive biomarker does not guarantee response.

It explains possible contributors including:

- heterogeneity;
- coexisting pathways;
- resistance;
- assay limitations;
- differences between specimens and disease sites.

# 22. Resistance QA

## Result: PASS

Resistance is included at conceptual level.

Detailed mechanisms are excluded.

This preserves ownership with therapy-specific resistance packages.

# 23. Tumor Heterogeneity QA

## Result: PASS

Tumor heterogeneity is included as an explanatory limitation.

The package does not overclaim that all tumor sites have identical biomarker status.

It also does not create a universal retesting rule.

# 24. Biomarker Reassessment QA

## Result: PASS

The package reflects the supplied NCCN framework that repeat biomarker assessment may be considered in selected progression settings.

It does not prescribe automatic retesting.

# 25. Safety and Toxicity QA

## Result: PASS

The package states that targeted therapy can have clinically significant toxicity.

A representative T-DXd example is used to demonstrate the benefit-burden principle.

Detailed toxicity management is delegated.

# 26. Patient-Facing Safety Language QA

## Result: PASS

The package avoids:

- “targeted therapy has no side effects”;
- “positive biomarker means guaranteed benefit”;
- “targeted therapy is always better”;
- “biomarker tells the doctor exactly what to prescribe.”

This is appropriate for patient-facing education.

# 27. Evidence-Date and Version QA

## Result: PASS

The primary disease-specific source is explicitly identified as:

**NCCN Gastric Cancer v2.2026, dated 01/21/2026 in the supplied source file.**

The NCI PDQ source supplied in the project is dated February 21, 2025.

The production date is separately recorded as 2026-08-09.

No source date is silently represented as a production date.

# 28. No Silent Reconciliation QA

## Result: PASS

Where sources serve different purposes, they are not forced into artificial uniformity.

- NCCN = disease-specific current treatment architecture.
- NCI PDQ = evidence synthesis.
- NCI patient-facing = patient explanation.
- ACS = patient-facing treatment context.
- ESMO-ASCO = professional educational framework.

The package does not silently replace the supplied source hierarchy with generic model knowledge.

# 29. No Unsupported Expansion QA

## Result: PASS

The package does not add:

- universal dosing;
- individualized regimens;
- universal sequencing;
- universal retesting;
- detailed assay protocols;
- unsupported target lists;
- unsupported treatment indications;
- detailed resistance algorithms.

# 30. Knowledge Graph QA

## Result: PASS

The Knowledge Graph identifies:

### Upstream

PP-0190, PP-0191 and biomarker-testing packages.

### Current

PP-0209.

### Downstream

PP-0210, PP-0211, PP-0212 and future target-specific packages.

### Parallel

PP-0208 and immunotherapy packages.

The routing rules are explicit and non-duplicative.

# 31. Boundary QA

## Result: PASS

The boundary is ownership-oriented.

### Core

Targeted therapy modality and its biomarker-linked clinical framework.

### Supporting

Representative drugs, targets, trials, and safety examples.

### Explicitly Excluded

Detailed testing, detailed drugs, dosing, toxicity, resistance, and individualized treatment.

### Delegated-to PP

Upstream biomarker/testing packages, PP-0208, PP-0210, PP-0211, PP-0212 and future therapy-specific packages.

The boundary is clean and consistent with adjacent ownership.

# 32. Cross-Artifact Consistency QA

| Concept | CKO | KP | EP | QA | Result |
|---|---|---|---|---|---|
| Atomic question | ✓ | ✓ | ✓ | ✓ | PASS |
| Targeted therapy definition | ✓ | ✓ | ✓ | ✓ | PASS |
| Biomarker relationship | ✓ | ✓ | ✓ | ✓ | PASS |
| HER2 | ✓ | ✓ | ✓ | ✓ | PASS |
| CLDN18.2 | ✓ | ✓ | ✓ | ✓ | PASS |
| VEGFR-2 | ✓ | ✓ | ✓ | ✓ | PASS |
| NTRK/BRAF/RET | ✓ | ✓ | ✓ | ✓ | PASS |
| Treatment-line context | ✓ | ✓ | ✓ | ✓ | PASS |
| Combination therapy | ✓ | ✓ | ✓ | ✓ | PASS |
| Resistance | ✓ | ✓ | ✓ | ✓ | PASS |
| Reassessment | ✓ | ✓ | ✓ | ✓ | PASS |
| Patient-facing content | ✓ | ✓ | ✓ | ✓ | PASS |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ | PASS |
| Boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Evidence gaps | ✓ | ✓ | ✓ | ✓ | PASS |
| Safety guardrails | ✓ | ✓ | ✓ | ✓ | PASS |

# 33. Artifact Depth Audit

## CKO

**PASS**

Full educational architecture, patient-facing explanation, treatment concepts, misconceptions, Knowledge Graph, boundary and key messages are present.

## Knowledge Passport

**PASS**

Runtime identity, classification, retrieval intent, routing, target map, safety guardrails, glossary, Knowledge Graph, maintenance triggers and boundary logic are present.

## Primary Evidence Package

**PASS**

Clinical question, scope, hierarchy, evidence matrices, target-specific evidence, trial register, evidence gaps, interpretation rules, provenance and update checklist are present.

## QA Report

**PASS**

Governance, scope, evidence, safety, boundary, overlap, Knowledge Graph, depth and cross-artifact audits are present.

# 34. Gold Depth Confirmation

## PASS

The package is not a compressed implementation.

The production retains the project's minimum Gold depth across:

- reasoning;
- clinical education;
- evidence traceability;
- patient-facing explanation;
- Knowledge Graph;
- boundary analysis;
- QA.

No artifact has been intentionally reduced to a short summary or reference card.

# 35. Final Clinical Integrity Statement

PP-0209 is clinically coherent as a **foundational targeted-therapy modality package**.

Its core ownership is:

> **How targeted therapy works as a treatment modality in gastric cancer and why biomarker information matters.**

It does not own:

- all systemic treatment;
- all biomarker testing;
- all biomarker-directed treatment selection;
- all targeted drugs;
- all targeted-therapy toxicities;
- all resistance mechanisms.

This ownership structure is the principal safeguard against duplication and scope drift.

# 36. Revision History

| Version | Date | Change |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA after PP-0209 Decision Batch approval and lock. |

---

# 37. Final QA Status

# PASS — GOLD — READY FOR INTEGRATION


# 37. Expanded QA — Atomicity

## Result: PASS

The package answers one clinical educational question:

> **What is targeted therapy for gastric cancer, how is it different from chemotherapy and immunotherapy, when can it be used, and why do biomarker results matter?**

It does not attempt to answer:

> “How is every targeted drug used?”

All major sections support the approved atomic question.

---

# 38. QA — Modality Ownership

## Result: PASS

PP-0209 owns:

**Targeted therapy as a treatment modality.**

It does not own:

**all targeted drugs.**

This is the central architectural distinction.

---

# 39. QA — Adjacent PP Overlap Matrix

| Adjacent PP | Their Ownership | PP-0209 Ownership | Duplication Risk | Result |
|---|---|---|---|---|
| PP-0190 | Biomarker-directed treatment selection | Targeted-therapy modality | Moderate | Controlled |
| PP-0191 | Biomarker testing strategy | Therapeutic relevance of testing | Moderate | Controlled |
| PP-0208 | Palliative systemic therapy | Targeted modality | Moderate | Controlled |
| PP-0210 | HER2-targeted therapy | HER2 as paradigm | High | Controlled |
| PP-0211 | CLDN18.2-targeted therapy | CLDN18.2 as paradigm | High | Controlled |
| PP-0212 | Anti-angiogenic therapy | VEGFR-2 as paradigm | High | Controlled |
| PP-0213 onward | Immunotherapy | Conceptual comparison | Moderate | Controlled |
| NGS PP | Molecular testing | Testing as upstream dependency | Low | Controlled |
| Molecular-report PP | Report interpretation | Target concept only | Low | Controlled |

---

# 40. QA — PP-0190 Versus PP-0209

### PP-0190

Owns the biomarker-directed treatment-selection bridge.

### PP-0209

Owns the broader targeted-therapy modality explanation.

PP-0209 does not reproduce the complete biomarker-directed decision framework.

Result: **PASS**.

---

# 41. QA — PP-0191 Versus PP-0209

### PP-0191

Owns:

- testing purpose;
- testing strategy;
- specimen considerations;
- broad testing options;
- testing limitations.

### PP-0209

Owns:

- therapeutic target;
- targeted modality;
- treatment implications at conceptual level.

Result: **PASS**.

---

# 42. QA — PP-0208 Versus PP-0209

### PP-0208

Owns:

- systemic treatment strategy;
- treatment-line architecture;
- palliative treatment context.

### PP-0209

Owns:

- targeted therapy as one modality within that broader system.

The package does not reproduce the complete systemic-treatment pathway.

Result: **PASS**.

---

# 43. QA — HER2 Boundary

PP-0209 contains only enough HER2 information to teach:

**biomarker → targeted treatment**.

It does not reproduce:

- detailed trastuzumab eligibility;
- full T-DXd algorithm;
- cardiac monitoring;
- ILD management;
- HER2 resistance;
- dose modification.

Result: **PASS**.

---

# 44. QA — CLDN18.2 Boundary

PP-0209 contains only enough CLDN18.2 information to teach:

**protein target → biomarker-selected therapy**.

It does not reproduce:

- detailed assay scoring;
- detailed zolbetuximab administration;
- detailed adverse-event management;
- detailed progression sequencing.

Result: **PASS**.

---

# 45. QA — Anti-Angiogenic Boundary

Ramucirumab is presented as a representative target/pathway example.

The package does not become an anti-angiogenic treatment manual.

Result: **PASS**.

---

# 46. QA — Rare Alteration Boundary

NTRK, BRAF V600E and RET are included to demonstrate:

**actionable target ≠ common gastric-cancer target**.

They are deliberately kept at supporting depth.

Result: **PASS**.

---

# 47. QA — Evidence Proportionality

## Result: PASS

Evidence depth is proportional to clinical relevance.

### High-depth evidence

- HER2;
- CLDN18.2;
- VEGFR-2.

### Supporting-depth evidence

- NTRK;
- BRAF V600E;
- RET.

This prevents rare alterations from appearing equivalent to major gastric-cancer treatment paradigms.

---

# 48. QA — Patient-Facing Accuracy

The package avoids:

- deterministic treatment language;
- guaranteed response claims;
- “targeted means harmless” claims;
- “targeted means mutation-only” claims;
- “targeted always beats chemotherapy” claims.

Result: **PASS**.

---

# 49. QA — Clinical Context Preservation

Each major example is presented with context:

- HER2 → advanced disease / treatment-line context;
- CLDN18.2 → selected HER2-negative advanced first-line context;
- ramucirumab → selected subsequent-line context;
- NTRK/BRAF/RET → selected molecularly defined circumstances.

Result: **PASS**.

---

# 50. QA — Evidence Layering

The package separates:

### Guideline-supported

from

### Context-dependent

from

### Emerging/evolving.

This prevents rare or evolving information from being presented as universally established.

Result: **PASS**.

---

# 51. QA — Treatment-Modality Comparison

The comparison with chemotherapy and immunotherapy is conceptual.

It does not claim universal superiority, universal sequencing, or universal combination.

Result: **PASS**.

---

# 52. QA — Combination-Therapy Safety

The package acknowledges that targeted therapy may be combined with chemotherapy and, in selected contexts, immunotherapy.

It does not imply that every patient should receive combination therapy.

Result: **PASS**.

---

# 53. QA — Target Is Not Mutation Check

The package explicitly includes:

- HER2 protein/expression;
- CLDN18.2 protein;
- VEGFR-2 receptor/pathway;
- NTRK fusion;
- BRAF V600E mutation;
- RET fusion.

Result: **PASS**.

---

# 54. QA — Negative-Test Interpretation

The package does not equate:

**negative target result**

with:

**absence of all molecular abnormalities**.

It preserves the distinction between a test result and the entire biology of the tumor.

Result: **PASS**.

---

# 55. QA — Positive-Test Interpretation

The package does not equate:

**positive target**

with:

**guaranteed response**.

It preserves treatment context, evidence, previous therapy, toxicity, and patient goals.

Result: **PASS**.

---

# 56. QA — Resistance Integrity

Resistance is included at conceptual level only.

No universal resistance mechanism is invented.

Result: **PASS**.

---

# 57. QA — Retesting Integrity

The package acknowledges that repeat biomarker assessment may be considered in selected progression settings.

It does not create an automatic retesting schedule.

Result: **PASS**.

---

# 58. QA — Patient Safety / Non-Prescriptive Rule

The package does not provide individualized instructions such as:

- start drug X;
- stop drug Y;
- switch to drug Z;
- repeat testing at a fixed interval.

Result: **PASS**.

---

# 59. QA — Source Fidelity

The package uses the supplied project source hierarchy.

No external web research was used to silently replace the project Source Materials.

Where the sources are context-dependent, the package preserves that uncertainty.

Result: **PASS**.

---

# 60. QA — Copyright-Safe Source Use

The package paraphrases source-derived clinical content and does not reproduce long source passages.

Source titles and roles are recorded for provenance.

Result: **PASS**.

---

# 61. QA — Version Integrity

The package records:

- PP version: 1.0.0;
- production date: 2026-08-09;
- NCCN source: v2.2026;
- governance: CORE_WORKING_RULES v1.7;
- artifact specification: FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1.

Result: **PASS**.

---

# 62. QA — Runtime Retrieval Safety

The package has explicit routing rules for:

- definition questions;
- biomarker questions;
- testing questions;
- drug-specific questions;
- systemic-treatment questions;
- toxicity questions.

Result: **PASS**.

---

# 63. QA — Maintenance Safety

The package contains update triggers for:

- target-list changes;
- treatment-status changes;
- treatment-line changes;
- major trial evidence;
- safety changes;
- biomarker-testing changes;
- downstream PP ownership changes.

Result: **PASS**.

---

# 64. QA — Repository Readiness

Required metadata is present.

Required four artifacts are present.

The ZIP package contains the four markdown artifacts.

Result: **PASS**.

---

# 65. QA — Cross-Artifact Semantic Consistency

The following terms have consistent meaning across all four artifacts:

- targeted therapy;
- biomarker;
- target;
- HER2;
- CLDN18.2;
- VEGFR-2;
- NTRK;
- BRAF V600E;
- RET;
- treatment line;
- resistance;
- reassessment;
- patient goals.

Result: **PASS**.

---

# 66. QA — Cross-Artifact Boundary Consistency

The same ownership logic appears in:

- CKO;
- Knowledge Passport;
- Evidence Package;
- QA.

Result: **PASS**.

---

# 67. QA — No Scope Drift

The package does not drift into:

- surgery;
- radiotherapy;
- chemotherapy regimen details;
- immunotherapy treatment details;
- detailed biomarker testing;
- detailed molecular-report interpretation;
- individualized prescribing.

Result: **PASS**.

---

# 68. QA — Gold Depth Reconfirmation

The package retains the project's established Gold depth across:

- reasoning;
- clinical education;
- evidence traceability;
- patient-facing explanation;
- Knowledge Graph;
- boundary analysis;
- QA.

No artifact has been intentionally reduced to a short summary or reference card.

Result: **PASS — GOLD**.

---

# 69. Final Four-Artifact Audit

| Domain | CKO | KP | EP | QA |
|---|---:|---:|---:|---:|
| Identity | ✓ | ✓ | ✓ | ✓ |
| Atomic question | ✓ | ✓ | ✓ | ✓ |
| Scope | ✓ | ✓ | ✓ | ✓ |
| Patient-facing education | ✓ | ✓ | ✓ | ✓ |
| Targeted therapy concept | ✓ | ✓ | ✓ | ✓ |
| Biomarker relationship | ✓ | ✓ | ✓ | ✓ |
| HER2 | ✓ | ✓ | ✓ | ✓ |
| CLDN18.2 | ✓ | ✓ | ✓ | ✓ |
| VEGFR-2 | ✓ | ✓ | ✓ | ✓ |
| NTRK/BRAF/RET | ✓ | ✓ | ✓ | ✓ |
| Treatment-line context | ✓ | ✓ | ✓ | ✓ |
| Combination therapy | ✓ | ✓ | ✓ | ✓ |
| Benefit/burden | ✓ | ✓ | ✓ | ✓ |
| Resistance | ✓ | ✓ | ✓ | ✓ |
| Reassessment | ✓ | ✓ | ✓ | ✓ |
| Patient questions | ✓ | ✓ | ✓ | ✓ |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ |
| Boundary | ✓ | ✓ | ✓ | ✓ |
| Evidence traceability | ✓ | ✓ | ✓ | ✓ |
| QA | ✓ | ✓ | ✓ | ✓ |

---

# 70. Final QA Conclusion

PP-0209 is internally coherent as the foundational targeted-therapy Population Package.

The package maintains:

**Biomarker testing**

→ **Biomarker-directed selection**

→ **Targeted therapy modality**

→ **Target-specific therapy**

This hierarchy prevents scope drift, duplicate drug content, biomarker-only treatment decisions, and unsupported individualized recommendations.

---

# 71. Final QA Status

# PASS — GOLD — READY FOR INTEGRATION


# 71. QA — Expanded Boundary Decision Audit

## Core

The core remains limited to targeted therapy as a modality and its relationship with biomarkers, clinical context, treatment line, benefit, burden, resistance, and patient education.

## Supporting

Representative targets, drugs, trials, and rare alterations support the modality explanation.

## Explicitly Excluded

Detailed testing, detailed drugs, dosing, detailed toxicity, detailed resistance, and individualized treatment remain excluded.

## Delegated

Upstream testing and selection packages and downstream target-specific packages remain authoritative.

Result: **PASS**.

---

# 72. QA — Scope Compression Check

Question:

**Has any clinically necessary Gold-depth content been removed merely to shorten the package?**

Answer:

**NO.**

The package contains:

- modality definition;
- biological rationale;
- biomarker relationship;
- target classes;
- major targets;
- rare targets;
- treatment-line context;
- combination strategies;
- benefits;
- limitations;
- resistance;
- reassessment;
- patient questions;
- Knowledge Graph;
- routing;
- safety guardrails.

Result: **PASS**.

---

# 73. QA — Hallucination Guard

The package was constructed from the supplied project Source Materials and locked PP-0209 Decision Batch.

No unsupported universal target list was introduced.

No unsupported universal testing algorithm was introduced.

No individualized treatment was invented.

Result: **PASS**.

---

# 74. QA — Terminology Consistency

| Term | Controlled meaning |
|---|---|
| Targeted therapy | Treatment designed around a specific biological target |
| Biomarker | Measurable biological information relevant to disease or treatment |
| Actionable | Clinically relevant to a potential treatment/trial option |
| Target | Biological feature addressed by a therapy |
| HER2-positive | Relevant HER2 overexpression/amplification state under the applicable testing framework |
| CLDN18.2-positive | Relevant CLDN18.2 expression state under the applicable testing framework |
| Resistance | Reduced or lost sensitivity to treatment |
| Tumor evolution | Change in tumor biology over time |
| Reassessment | New clinical and/or biomarker evaluation when clinically appropriate |

Result: **PASS**.

---

# 75. QA — Patient-Facing Reading Flow

The package supports the following learning sequence:

1. What is targeted therapy?
2. Why does it need a target?
3. Why is biomarker testing important?
4. How is it different from chemotherapy?
5. How is it different from immunotherapy?
6. What targets matter in gastric cancer?
7. When can targeted therapy be used?
8. What benefits are possible?
9. What side effects are possible?
10. Why might it stop working?
11. Could the biomarker change?
12. What should I ask my care team?

Result: **PASS**.

---

# 76. QA — Retrieval Flow

The package supports:

**broad query**

→ PP-0209

**target-specific query**

→ downstream PP

**testing query**

→ upstream testing PP

**systemic-treatment query**

→ PP-0208 / appropriate treatment package

**toxicity query**

→ therapy-specific toxicity package

Result: **PASS**.

---

# 77. QA — Maintenance and Versioning

The package identifies the principal maintenance triggers:

- guideline revision;
- new targeted therapy;
- new target;
- new safety signal;
- new major trial;
- treatment-line change;
- testing change;
- downstream PP creation.

Result: **PASS**.

---

# 78. QA — Knowledge Graph Stability

The package does not require reordering the entire treatment knowledge graph when a new targeted therapy is added.

A new therapy can be inserted downstream while PP-0209 remains the modality-level node.

Result: **PASS**.

---

# 79. QA — Duplicate-PP Prevention

Before creating a future targeted-treatment PP, verify whether PP-0209 already owns the topic.

If the new PP is:

- drug-specific;
- target-specific;
- toxicity-specific;
- resistance-specific;
- testing-specific;

it can be downstream without duplicating the modality-level explanation.

Result: **PASS**.

---

# 80. QA — Patient Safety Conclusion

The package is educational rather than prescriptive.

It does not tell a patient to:

- start;
- stop;
- switch;
- delay;
- repeat;
- refuse

a particular treatment.

Result: **PASS**.

---

# 81. QA — Final Architecture Statement

PP-0209 is the stable conceptual bridge:

**Molecular / biomarker information**

→ **Targeted treatment modality**

→ **Target-specific therapy**

The package therefore remains useful even as individual targeted agents change.

Result: **PASS**.

---

# 82. Final Production Readiness

| Requirement | Status |
|---|---|
| Approved scope preserved | PASS |
| Gold depth preserved | PASS |
| Source-first | PASS |
| Evidence-grounded | PASS |
| Patient-facing | PASS |
| Knowledge Graph | PASS |
| Boundary | PASS |
| Adjacent overlap | PASS |
| Safety | PASS |
| Four artifacts | PASS |
| ZIP | PASS |
| Ready for integration | PASS |
